Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs
This article was originally published in The Pink Sheet Daily
A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.
You may also be interested in...
Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.
“We do not believe that we have the authority under the Budget Control Act of 2011 to exempt Medicare payment for Part B drugs,” CMS Administrator Marilyn Tavenner told members of Congress in a June 3 letter.
Wholesalers AmerisourceBergen and McKesson discuss the potential impact of the federal budget sequester and the resulting cut to Part B drug reimbursement on oncology drug sales.